0001213900-26-034372
SEC filingAscentage Pharma Group International reported full year 2025 unaudited financial results with product sales and commercial rights revenues of US$82.1 million, up 90% year-over-year, driven by Olverembatinib sales of US$62.2 million (up 81%) and Lisaftoclax sales of US$10.1 million since launch, alongside updates on nine ongoing registrational Phase III trials.